Biomedical Engineering Reference
In-Depth Information
128. Le Saux S, Rousseau F, Barbier F, Ravon E, Grimaud L,
Danger Y, et al. (2010) Molecular dissection of human
interleukin-31-mediated signal transduction through site-
directed mutagenesis. J. Biol. Chem. 285, 3470-3477.
129. Kouzarides T, Ziff E. (1989) Leucine zippers of fos, jun and
GCN4 dictate dimerization specificity and thereby control
DNA binding. Nature 340, 568-571.
130. Gearing DP, Comeau MR, Friend DJ, Gimpel SD, Thut CJ,
McGourty J, et al. (1992) The IL-6 signal transducer, gp130:
an oncostatin M receptor and affinity converter for the LIF
receptor. Science 255, 1434-1437.
131. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H,
Koishihara Y, et al. (1993) Soluble forms of the interleu-
kin-6 signal-transducing receptor component gp130 in human
serum possessing a potential to inhibit signals through mem-
brane-anchored gp130. Blood 82, 1120-1126.
132. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N,
et al. (2001) Soluble gp130 is the natural inhibitor of soluble
interleukin-6 receptor transsignaling responses. Eur. J. Bio-
chem. 268, 160-167.
133. Crowe J, Dobeli H, Gentz R, Hochuli E, Stuber D, Henco K.
(1994) 6xHis-Ni-NTA chromatography as a superior tech-
nique in recombinant protein expression/purification. Meth-
ods Mol. Biol. 31, 371-387.
134. Yu JR, Leslie KS. (2011) Cryopyrin-associated periodic
syndrome: an update on diagnosis and treatment response.
Curr. Allergy Asthma Rep. 11, 12-20.
135. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J.
(2006) Gout-associated uric acid crystals activate the
NALP3 inflammasome. Nature 440, 237-241.
136. Torres R, Macdonald L, Croll SD, Reinhardt J, Dore A,
Stevens S, et al. (2009) Hyperalgesia, synovitis and multiple
biomarkers of inflammation are suppressed by interleukin 1
inhibition in a novel animal model of gouty arthritis. Ann.
Rheum. Dis. 68, 1602-1608.
137. So A, De Smedt T, Revaz S, Tschopp J. (2007) A pilot study
of IL-1 inhibition by anakinra in acute gout. Arthritis Res.
Ther. 9, R28.
138. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Book-
binder S, Biedermann S, et al. (2009) The interleukin 1
inhibitor rilonacept in treatment of chronic gouty arthritis:
results of a placebo-controlled, monosequence crossover,
non-randomised, single-blind pilot study. Ann. Rheum. Dis.
68, 1613-1617.
139. Burns CM, Wortmann RL. (2011) Gout therapeutics: new
drugs for an old disease. Lancet 377, 165-177.
140. Glaser DL, Economides AN, Wang L, Liu X, Kimble RD,
Fandl JP, et al. (2003) In vivo somatic cell gene transfer of an
engineered Noggin mutein prevents BMP4-induced hetero-
topic ossification. J. Bone Joint Surg. Am. 85-A, 2332-2342.
141. Paine-Saunders S, Viviano BL, Economides AN, Saunders S.
(2002) Heparan sulfate proteoglycans retain Noggin at the
cell surface: a potential mechanism for shaping bone mor-
phogenetic protein gradients. J. Biol. Chem. 277, 2089-2096.
142. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M,
et al. (2002) VEGF-Trap: a VEGF blocker with potent antitumor
effects. Proc.Natl.Acad.Sci.USA99, 11393-11398.
143. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW,
Frischer JS, et al. (2002) Potent VEGF blockade causes
regression of coopted vessels in a model of neuroblastoma.
Proc. Natl. Acad. Sci. USA 99, 11399-11404.
144. Chiang A, Regillo CD. (2011) Preferred therapies for
neovascular age-related macular degeneration. Curr. Opin.
Ophthalmol. 22, 199-204.
145. Teng LS, Jin KT, He KF, Zhang J, Wang HH, Cao J. (2010)
Clinical applications of VEGF-trap (aflibercept) in cancer
treatment. J. Chin. Med. Assoc. 73, 449-456.
146. Twardowski P, StadlerWM, Frankel P, Lara PN, Ruel C, Chatta
G, et al. (2010) Phase II study of Aflibercept (VEGF-Trap)
in patients with recurrent or metastatic urothelial cancer, a
California Cancer Consortium Trial. Urology 76, 923-926.
147. Cai J, Han S, Qing R, Liao D, Law B, Boulton ME. (2011) In
pursuit of new anti-angiogenic therapies for cancer treatment.
Front. Biosci. 16, 803-814.
148. J. F. de Groot, K. R. Lamborn, S. M. Chang, M. R. Gilbert,
T. F. Cloughesy, K. Aldape, J. Yao, E. F. Jackson, F. Lieberman,
H. I. Robins, M. P. Mehta, A. B. Lassman, L. M. Deangelis,
W. K. Yung, A. Chen, M. D. Prados, P. Y. Wen. (2011). Phase II
study of aflibercept in recurrent malignant glioma: a North
American Brain Tumor Consortium study. Journal of clinical
oncology : official journal of the American Society of Clinical
Oncology, 29, 2689-2695.
149. Ferrara N, Hillan KJ, Gerber HP, Novotny W. (2004) Discov-
ery and development of bevacizumab, an anti-VEGF antibody
for treating cancer. Nat. Rev. Drug Discov. 3, 391-400.
150. Ferrara N, Damico L, Shams N, Lowman H, Kim R. (2006)
Development of ranibizumab, an anti-vascular endothelial
growth factor antigen binding fragment, as therapy for neo-
vascular age-related macular degeneration. Retina 26, 859-870.
151. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC,
Lowman HB, et al. (1998) VEGF and the Fab fragment of a
humanized neutralizing antibody: crystal structure of the
complex at 2.4 A resolution and mutational analysis of the
interface. Structure 6, 1153-1167.
152. Stewart MW, Rosenfeld PJ. (2008) Predicted biological activ-
ity of intravitreal VEGF Trap. Br. J. Ophthalmol. 92, 667-668.
153. Brown DM, Heier JS, Ciulla T, Benz M, Abraham P, Yanco-
poulos G, et al. (2011) Primary endpoint results of a phase II
study of vascular endothelial growth factor trap-eye in wet
age-related macular degeneration. Ophthalmology 118,
1089-1097.
154. Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB,
Yancopoulos G, et al. (2011) The 1-year results of
CLEAR-IT 2, a Phase 2 study of vascular endothelial growth
factor trap-eye dosed as-needed after 12-week fixed dosing.
Ophthalmology 118, 1098-1106.
155. D. V. Do, U. Schmidt-Erfurth, V. H. Gonzalez, C. M. Gordon,
M. Tolentino, A. J. Berliner, R. Vitti, R. Ruckert, R.
Sandbrink, D. Stein, K. Yang, K. Beckmann, J. S. Heier.
(2011). The DA VINCI Study: phase 2 primary results of
VEGF Trap-Eye in patients with diabetic macular edema.
Ophthalmology, 118, 1819-1826.
156. Allendorph GP, Isaacs MJ, Kawakami Y, Izpisua Belmonte
JC, Choe S. (2007) BMP-3 and BMP-6 structures illuminate
Search WWH ::
Custom Search